Main Products/ Services/ Pipelines & Platforms
Cell Technology Platforms: ▪ Three unique cell technology platforms, named DashCAR®, MaxCAR®, and OneCAR®, for CAR immune cell therapy. Main Product: ARD103 (CLL-1 DashCAR®-T) Indication: blood cancer relapsed/refractory AML Target: Human C-type lectin-like molecule 1 (CLL-1) ▪ The median of positive expression rate of CLL-1 in tumor cells of all patients was 85.2% (range 50.2%-97.6%). ▪ CLL-1 is expressed on both blasts and leukemia stem cells, but not on hematopoietic stem cells. Product Features: ▪ Ultrafast DashCAR® bioprocess in 3 days ▪ High productivity with > 80% CAR+ ▪ Engineered cells conserving stemness > 80% ▪ High specificity without off-target issues ▪ Safe with limited hematotoxicity ▪ Proved efficacy & durability in animal models ▪ IND-enabling targeted IND in Q4/2023
Business Interests
▪ CLL-1 CAR-T product early-entry to the market ▪ Seek partners to collaborate the U.S. and global clinical development ▪ Seek out-licensing opportunity
Contact Info
Chien-Tsun Kuan
President / CEO
(919) 961-6163 (U.S.) 886+909-576-846 (Taiwan)
ct_kuan@ARCEtherapeutics.com
Li-Ming Lu
Project Manager/Business Development
+886 920 787 815(Taiwan)
liming_lu@arcetherapeutics.com